Mereo Biopharma Group PLC
NASDAQ:MREO
Income Statement
Earnings Waterfall
Mereo Biopharma Group PLC
Revenue
|
7.1m
GBP
|
Cost of Revenue
|
-1.9m
GBP
|
Gross Profit
|
5.3m
GBP
|
Operating Expenses
|
-36.9m
GBP
|
Operating Income
|
-31.7m
GBP
|
Other Expenses
|
5.6m
GBP
|
Net Income
|
-26.1m
GBP
|
Income Statement
Mereo Biopharma Group PLC
Jun-2020 | Dec-2020 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | ||
---|---|---|---|---|---|---|---|
Revenue | |||||||
Revenue |
0
N/A
|
0
N/A
|
36
N/A
|
0
N/A
|
0
N/A
|
7
N/A
|
|
Gross Profit | |||||||
Cost of Revenue |
0
|
0
|
(18)
|
1
|
1
|
(2)
|
|
Gross Profit |
0
N/A
|
0
N/A
|
19
N/A
|
1
-97%
|
1
+62%
|
5
+459%
|
|
Operating Income | |||||||
Operating Expenses |
(38)
|
(38)
|
(39)
|
(43)
|
(45)
|
(37)
|
|
Selling, General & Administrative |
(18)
|
(21)
|
(16)
|
(16)
|
(20)
|
(20)
|
|
Research & Development |
(20)
|
(16)
|
(24)
|
(27)
|
(25)
|
(20)
|
|
Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
3
|
|
Operating Income |
(38)
N/A
|
(38)
+1%
|
(21)
+44%
|
(43)
-103%
|
(44)
-2%
|
(32)
+27%
|
|
Pre-Tax Income | |||||||
Interest Income Expense |
(5)
|
(118)
|
35
|
25
|
7
|
4
|
|
Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
|
Gain/Loss on Disposition of Assets |
(11)
|
(11)
|
0
|
0
|
0
|
0
|
|
Total Other Income |
(95)
|
(0)
|
(0)
|
0
|
0
|
(1)
|
|
Pre-Tax Income |
(149)
N/A
|
(166)
-12%
|
14
N/A
|
(17)
N/A
|
(36)
-118%
|
(28)
+22%
|
|
Net Income | |||||||
Tax Provision |
5
|
3
|
(2)
|
(2)
|
2
|
2
|
|
Income from Continuing Operations |
(143)
|
(164)
|
13
|
(19)
|
(34)
|
(26)
|
|
Net Income (Common) |
(143)
N/A
|
(164)
-14%
|
13
N/A
|
(19)
N/A
|
(34)
-85%
|
(26)
+24%
|
|
EPS (Diluted) |
-1.2
N/A
|
-0.48
+60%
|
0.02
N/A
|
-0.03
N/A
|
-0.06
-100%
|
-0.04
+33%
|